Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Don Robinson

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
European Journal of Haematology|April 4, 2012
Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trialMichel Delforge, Ravinder Dhawan, Don Robinson, et al.
Arthritis Care & Research|March 2, 2010
Impact of systemic lupus erythematosus on health, family, and work: the patient perspectiveDon Robinson, Daniel Aguilar, Melissa Schoenwetter, et al.
British Journal of Haematology|January 7, 2014
Clinical epidemiology and treatment patterns of patients with multicentric Castleman disease: results from two US treatment centresDon Robinson, Matthew Reynolds, Corey Casper, et al.
The Journal of Supportive Oncology|February 9, 2008
A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexiaBertram Wiedenmann, Peter Malfertheiner, Helmut Friess, et al.
British Journal of Haematology|July 9, 2015
Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-upHeinz Ludwig, Richard Greil, Tamas Masszi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2012
Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myelomaHeinz Ludwig, Luisa Viterbo, Richard Greil, et al.
Health Science Reports|January 31, 2019
Bortezomib retreatment for relapsed and refractory multiple myeloma in real-world clinical practiceCyrille Hulin, Javier de la Rubia, Meletios A Dimopoulos, et al.
European Journal of Haematology|July 21, 2018
Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practiceEvangelos Terpos, Eirini Katodritou, Javier de la Rubia, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
European Journal of Haematology|April 4, 2012
Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trialMichel Delforge, Ravinder Dhawan, Don Robinson, et al.
Arthritis Care & Research|March 2, 2010
Impact of systemic lupus erythematosus on health, family, and work: the patient perspectiveDon Robinson, Daniel Aguilar, Melissa Schoenwetter, et al.
British Journal of Haematology|January 7, 2014
Clinical epidemiology and treatment patterns of patients with multicentric Castleman disease: results from two US treatment centresDon Robinson, Matthew Reynolds, Corey Casper, et al.
The Journal of Supportive Oncology|February 9, 2008
A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexiaBertram Wiedenmann, Peter Malfertheiner, Helmut Friess, et al.
British Journal of Haematology|July 9, 2015
Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-upHeinz Ludwig, Richard Greil, Tamas Masszi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2012
Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myelomaHeinz Ludwig, Luisa Viterbo, Richard Greil, et al.
Health Science Reports|January 31, 2019
Bortezomib retreatment for relapsed and refractory multiple myeloma in real-world clinical practiceCyrille Hulin, Javier de la Rubia, Meletios A Dimopoulos, et al.
European Journal of Haematology|July 21, 2018
Bortezomib-based therapy for relapsed/refractory multiple myeloma in real-world medical practiceEvangelos Terpos, Eirini Katodritou, Javier de la Rubia, et al.
Pageof 4